NCT01393561已完成3 期
Multicenter Clinical Trial, Phase III, Randomized, Double-blind, Placebo Controlled, Comparative for Evaluate the Efficacy and Safety of Fixed Dose Combination of Brompheniramine Maleate + Phenylephrine Chlorhydrate for the Treatment of Nasal Congestion and Runny Nose Present in Acute Crisis of Viral Rhinitis (Common Cold) and Allergic Reactions, in Patients Over 12 Years Old
Ache Laboratorios Farmaceuticos S.A.0 个研究点目标入组 167 人开始时间: 2014年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 167
- 主要终点
- Improvement of nasal congestion and runny nose, after 48 hours of treatment
研究概览
简要总结
This is a multicenter clinical trial, phase III, superiority, controlled by active medicine, double-blind, randomized, enroll 166 children, over 12 years old, with acute inflammation upper airway, characterized by nasal congestion and runny nose, lasting at least 24 hours and a maximum of 48 hours prior to inclusion. The subjects will be allocated in 2 parallel groups, and will receive the medicines of study, according of the randomization.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients over 12 years old, of both sexes, remaining the feasibility of a legal representant according to need, able to understand and provide ICF and able to allow compliance to treatment and the requirements of the protocol, according to age group;
- •Patients with symptoms of acute inflammation upper airway, starting between 24 and 48 hours of their inclusion in this study protocol;
- •Presence of runny nose classification moderate or severe (score 2 or 3), according the responsible evaluation,
- •Presence of nasal congestion classification moderate or severe (score 2 or 3), according the responsible evaluation.
排除标准
- •Patients under 12 years old or weight less than 40kg;
- •History of nasal obstruction in chronic rhinosinusitis and / or nasal polyposis;
- •Oral chronic respirator with history for six months;
- •Personal history of nasal surgery that in the opinion of the investigator can influence the resistance to nasal airflow;
- •Patients who have a clinical history confirmed (diagnosed) with asthma;
- •Patients under medicine treatment for chronic allergy;
- •Patients with gastroesophageal reflux disease;
- •Presence of psychiatric illness of any kind;
- •Presence of mental retardation from any cause;
- •Diagnosis of renal or hepatic failure;
- •Patients with genetic syndromes;
- •History of hypersensitivity to (s) drug (s) of study or their excipients;
- •Use of prohibited medicine within the prescribed period before the V0 - Inclusion Visit (Table 1);
- •Patients who participated in the last 12 months, of clinical trials protocols;
- •Patients who didn´t updated vaccine book, according to age group;
- •Relatives of sponsor´s or study site´s employee;
- •Suggestive signs of bacterial infection of upper airways at rhinoscopy, otoscopy or oroscopy;
- •Presence of anemic/inflamed turbinate at anterior rhinoscopy;
- •Presence of septal deviation grade II and III (in any region and any nasal cavity) and / or nasal polyps, or other conditions determinants of nasal obstruction;
- •Presence of purulent or mucopurulent secretion, nasal vault or mal formations (cleft lip or cleft nasolabial corrected or not) in nasal vestibule;
- •Current evidence of clinically significant diseases: hematopoietic, gastrointestinal, cardiovascular, hepatic, renal, neurological, endocrine, psychiatric, autoimmune, pulmonary, or another disease that block the patient participation;
- •Any finding of clinical observation (anamnesis and physical exam) laboratory abnormality (eg, blood glucose, blood count), disease (for example, liver, cardiovascular system, lung) or therapy that, in opinion of the investigator, may endanger the patient or interfere with the endpoints of study.
研究组 & 干预措施
Group 1
Experimental
Fixed dose combination of brompheniramine + phenylephrine.
干预措施: Group 1 (Drug)
Group 2
Placebo Comparator
Placebo
干预措施: Group 2 (Drug)
结局指标
主要结局
Improvement of nasal congestion and runny nose, after 48 hours of treatment
时间窗: 48 hours after single dose of double-blind treatment
Improvement is defined as a reduction of at least one point on the rating scale, in both nasal symptoms, after 48 hours of treatment. Participants were evaluated (self-assessment) for pain intensity by using a 4-point rating scale: 0=none, 1=mild, 2=moderate, and 3=severe.
次要结局
- Safety descriptive about occurence of adverse events, evaluation of results of general physical examination.(Will be evaluated during the 5(± 1) days of treatment)
- Proportion of subjects who used at least once the rescue medication(Within 2 days and the period of 5 (± 1) days of treatment)
- Clinical score of upper airway compromise(After 2 and 5 (± 1) days of treatment)
- Overall score of nasal and extranasal symptoms (nasal congestion, runny nose, sneezing, watery eyes and itching)(After 2 and 5 (± 1) days of treatment.)
研究者
相似试验
撤回
3 期
Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of Diphenhydramine + Pseudoephedrine + Dropropizine in the Control of Cough and the Relief of Nasal Symptoms, Suffering From Non-productive Cough and Acute RhinitisNasal CongestionCoughNCT01199497Ache Laboratorios Farmaceuticos S.A.
已完成
3 期
Efficacy and Safety of Combination of Brompheniramine and Phenylephrine for the Symptoms Relief of RhinitisNasal Congestion and InflammationsRhinitisNCT01393548Ache Laboratorios Farmaceuticos S.A.879
Unknown
3 期
A Study to Evaluate the Efficacy and Safety of DA-5204Acute GastritisChronic GastritisNCT02282670Dong-A ST Co., Ltd.434
Unknown
3 期
A Study to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034Acute GastritisChronic GastritisNCT01813812Dong-A Pharmaceutical Co., Ltd.492
撤回
3 期
Evaluation of Efficacy and Safety in Control Cough and the Relief of Nasal Symptoms in Children 2-12 Years Old,Suffering From Cough and Acute RhinitisInflammationCoughRhinitisNCT01177852Ache Laboratorios Farmaceuticos S.A.